Benazepril Hydrochloride

證據等級: L5

預測適應症: 0 個

Benazepril Hydrochloride: Drug Repurposing Evaluation — Preliminary Report

One-Sentence Summary

Benazepril Hydrochloride is an ACE inhibitor currently marketed in Malaysia with 2 registered products. No new indications have been predicted by TxGNN at this time, and critical data gaps (DrugBank ID, MOA, approved indication text, and safety information) must be resolved before a full evaluation can proceed.

Quick Overview

Item	Content
Original Indication	(Data not available — license indication text is empty)
Predicted New Indication	None — no TxGNN predictions generated
TxGNN Prediction Score	N/A
Evidence Level	L5 (No prediction, no studies to evaluate)
Malaysia Market Status	✓ Marketed (已上市)
Number of Registrations	2
Recommended Decision	Hold

Why is This Prediction Reasonable?

There is currently no TxGNN prediction available for Benazepril Hydrochloride. The predicted_indications array is empty, meaning the model either has not been run for this drug or no candidates met the scoring threshold.

Currently, detailed mechanism of action data is not available in this evidence pack. Based on publicly known information, Benazepril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and aldosterone secretion. It is widely used for the treatment of hypertension and congestive heart failure. This class of drugs has also been investigated for renoprotective effects in diabetic nephropathy and other conditions.

Before a drug repurposing assessment can proceed, the TxGNN prediction pipeline must be executed with a valid DrugBank mapping for Benazepril (DrugBank ID: DB00542, based on known public data) to generate candidate indications.

Clinical Trial Evidence

Currently no predicted indication to search against. Clinical trial evidence will be gathered once a TxGNN prediction is available.

Literature Evidence

Currently no predicted indication to search against. Literature evidence will be gathered once a TxGNN prediction is available.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(empty)	(empty)	(empty)	(empty)
(empty)	(empty)	(empty)	(empty)

Note: Two registrations were found by the NPRA query (query date: 2026-03-27), but the license detail fields (authorization number, product name, dosage form, approved indication) are all empty in this evidence pack. These need to be re-extracted from the NPRA database.

Safety Considerations

Please refer to the package insert for safety information. All safety fields (key warnings, contraindications, drug interactions) are currently missing from this evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: This evaluation cannot proceed because there are no TxGNN predicted indications and multiple critical data gaps remain unresolved. The evidence pack is incomplete at the most fundamental level — without a predicted indication, no repurposing assessment can be performed.

To proceed, the following is needed:

DrugBank ID mapping — Confirm DrugBank ID (likely DB00542) and integrate into the evidence pack
Re-run TxGNN prediction — Execute the KG and DL prediction pipeline with the correct DrugBank mapping to generate candidate indications
Populate NPRA license details — Re-query the NPRA database to fill in authorization numbers, product names, dosage forms, and approved indication text for the 2 registered products
Obtain MOA data — Query DrugBank API to retrieve the mechanism of action (ACE inhibition pathway)
Obtain safety data — Download and parse the package insert (仿單) PDF from NPRA/manufacturer to extract warnings, contraindications, and drug interaction information
Evidence collection — Once a predicted indication is available, run ClinicalTrials.gov, PubMed, and ICTRP collectors for supporting evidence

Data Gaps Summary

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.